Menu
Back to Journals » Clinical Interventions in Aging » Volume 4
The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
Published 23 April 2009 Volume 2009:4 Pages 191—196
DOI https://doi.org/10.2147/CIA.S4233
Review by Single anonymous peer review
Peer reviewer comments 2
Danny Ulahannan, Adrian Wagg
Department of Geriatric Medicine, University College Hospital, London, UK
Abstract: After lifestyle and behavioral measures to control overactive bladder, the mainstay of pharmacological treatment is the use of antimuscarinic therapy. Overactive bladder predominantly affects older people, who experience the most severe disease, and are also at a greater risk of side effects from antimuscarinic therapy. Thus it is imperative that data are available on the efficacy and tolerability of this group of drugs when used in older people. This article reviews the pathophysiology of the condition, its effect on the elderly and the evidence for the use of extended release tolterodine in the elderly using data from placebo and active drug controlled studies.
Keywords: overactive bladder, tolterodine, urgency incontinence
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.